• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Boston Scientific touts improved back pain relief in Spectra SCS trial

Boston Scientific touts improved back pain relief in Spectra SCS trial

December 11, 2015 By Fink Densford

Boston ScientificBoston Scientific (NYSE:BSX) today released data from the Lumina trial of its Precision Spectra spinal cord stimulator, touting a 70% improvement in back pain relief over its previous generation Precision Plus SCS.

Data from the Lumina study is being presented at the North American Neuromodulation Society’s annual meeting in Las Vegas this weekend, the company said.

“As the Lumina data show, the Boston Scientific Illumina 3D Algorithm allows me to treat low back pain more consistently and effectively than before. These data are impressive because they demonstrate sustained long term pain relief in an all-comers population; we did not exclude the type of challenging patients that physicians see every day,” Dr. James North of the Carolinas Pain Institute said in prepared remarks.

Marlborough, Mass.-based Boston Scientific said data from the study showed a significant decrease in average pain scores over a 2-year period and when the device was combined with the company’s CoverEdge surgical lead, demonstrated increased pain relief at 12 months. Boston Scientific gave credit for the increased pain relief to the device’s Illumina 3D neural targeting algorithm.

“We designed the Precision Spectra SCS System with the flexibility to deliver multiple waveforms using our powerful Illumina 3D Algorithm. These conclusive Lumina real-world clinical data demonstrate that the Precision Spectra SCS System is a significant advancement for improving the lives of patients with chronic pain,” neuromod prez Maulik Nanavaty said in a press release.

The test examined a total of 576 patients in 4 cohorts that compared its last generation SCS system to the Spectra, as well as the effect of its CoverEdge 32 surgical lead and a cohort in which disability was measured out to 12 months, the company said.

Boston Scientific said its Spectra-treated group demonstrated an average reduction from a baseline pain score of 7.17 to 2.94 at 24 months, and in a subset of severe patients with lower back pain, reported an average reduction from 8.6 to 2.98.

In the between-group study comparing the Spectra to the last-gen SCS, the company said it saw a 70% improvement in lower back pain scores between the 2 devices.

The cohort treated with its CoverEdge 32 surgical lead reported an average reduction from 7.8 to 2.6 at 12 months, and the disability-monitored group reported a reduction of more than 20 points over 12 months, as measured by the Oswestry Disability Index.

Filed Under: Clinical Trials, Neuromodulation/Neurostimulation, Pain Management, Spine Tagged With: Boston Scientific

More recent news

  • Medtronic reports first patient treated in study of multi-organ denervation for hypertension
  • Baxter turns to an automation company for its new CEO
  • Pristine Surgical appoints new CFO
  • Boston Scientific wins expanded FDA nod for Farapulse PFA
  • FDA warns on issue with J&J Abiomed pump controllers related to 3 deaths

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy